eXoZymes (NASDAQ:EXOZ) Shares Up 0.4% – Should You Buy?

eXoZymes Inc. (NASDAQ:EXOZ)’s stock price traded up 0.4% on Thursday . The company traded as high as $13.48 and last traded at $12.20. 11,195 shares traded hands during trading, an increase of 288% from the average session volume of 2,883 shares. The stock had previously closed at $12.15.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of eXoZymes in a research report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, eXoZymes presently has a consensus rating of “Sell”.

eXoZymes Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.53 and a current ratio of 4.53. The business has a 50 day moving average price of $14.11 and a 200-day moving average price of $12.30. The company has a market capitalization of $102.32 million and a price-to-earnings ratio of -15.84.

eXoZymes (NASDAQ:EXOZ) last issued its earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share for the quarter.

About eXoZymes

eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.